Similar to quizartinib and gilteritinib, the combination of azacitidine with sorafenib also synergistically inhibited MOLM-13 and MV4-11 cell growth, induced apoptosis, and decreased tumor volume in xenograft mouse model of FLT3-ITD AML. Here, FLT3 is linked to acute myeloid leukemia.